Somatic V600E BRAF Mutation in Linear and Sporadic Syringocystadenoma Papilliferum

Overview

Journal J Invest Dermatol

Publisher Elsevier

Specialty Dermatology

Date 2015 May 8

PMID 25950823

Citations 8

Authors

Jonathan L Levinsohn

Jeffrey L Sugarman

Kaya Bilguvar

Jennifer M McNiff

Keith A Choate

The Yale Center For Mendelian Genomics

Affiliations

Soon will be listed here.

Citing Articles

Mutational analysis of BRAFV600E in a case of sialadenoma papilliferum of oral cavity.

Jot K, Sharath R, Bhutia O, Surya V J Oral Maxillofac Pathol. 2024; 28(3):488-492.

PMID: 39670117 PMC: 11633923. DOI: 10.4103/jomfp.jomfp_72_24.

Somatic Mosaicism in Blaschkolinear Inflammatory Disorders.

Theodosakis N, Levy L, Cowper S, Lazova R, Kugelman L, Zubek A J Clin Exp Dermatol Res. 2022; 7(4).

PMID: 36267522 PMC: 9581078. DOI: 10.4172/2155-9554.1000356.

Case Report: Papillary Lesions at the Mouth Floor May Mimic Sialadenoma Papilliferum.

Han D, Cho E, Park J, Kim D Pathol Oncol Res. 2022; 28:1610352.

PMID: 35911440 PMC: 9329833. DOI: 10.3389/pore.2022.1610352.

Analyzing the Spatial Randomness in the Distribution of Acquired Melanocytic Neoplasms.

Chousakos E, Kose K, Kurtansky N, Dusza S, Halpern A, Marghoob A J Invest Dermatol. 2022; 142(12):3274-3281.

PMID: 35841946 PMC: 10475172. DOI: 10.1016/j.jid.2022.06.011.

Neonatal syringocystadenoma papilliferum: A case report.

Jiang H, Zhang Z, Zhang L, Pu Y, Zhou N, Shu H World J Clin Cases. 2021; 9(18):4772-4777.

PMID: 34222446 PMC: 8223827. DOI: 10.12998/wjcc.v9.i18.4772.

References

Krumm N, Sudmant P, Ko A, ORoak B, Malig M, Coe B . Copy number variation detection and genotyping from exome sequence data. Genome Res. 2012; 22(8):1525-32. PMC: 3409265. DOI: 10.1101/gr.138115.112. View

Thorvaldsdottir H, Robinson J, Mesirov J . Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2012; 14(2):178-92. PMC: 3603213. DOI: 10.1093/bib/bbs017. View

Sarin K, Sun B, Bangs C, Cherry A, Swetter S, Kim J . Activating HRAS mutation in agminated Spitz nevi arising in a nevus spilus. JAMA Dermatol. 2013; 149(9):1077-81. DOI: 10.1001/jamadermatol.2013.4745. View

Lim Y, Ovejero D, Sugarman J, DeKlotz C, Maruri A, Eichenfield L . Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet. 2013; 23(2):397-407. PMC: 3869357. DOI: 10.1093/hmg/ddt429. View

Satter E, Grady D, Schlocker C . Syringocystadenocarcinoma papilliferum with locoregional metastases. Dermatol Online J. 2014; 20(4):22335. View

Krishnaswami S, Kumar S, Ordoukhanian P, Yu B . Fate and plasticity of the epidermis in response to congenital activation of BRAF. J Invest Dermatol. 2014; 135(2):481-9. PMC: 4289449. DOI: 10.1038/jid.2014.388. View

Shen A, Peterhof E, Kind P, Rutten A, Zelger B, Landthaler M . Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum. Hum Pathol. 2014; 46(2):272-6. DOI: 10.1016/j.humpath.2014.11.002. View

Groesser L, Herschberger E, Ruetten A, Ruivenkamp C, Lopriore E, Zutt M . Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet. 2012; 44(7):783-7. DOI: 10.1038/ng.2316. View

Boni R, Xin H, Hohl D, Panizzon R, Burg G . Syringocystadenoma papilliferum: a study of potential tumor suppressor genes. Am J Dermatopathol. 2001; 23(2):87-9. DOI: 10.1097/00000372-200104000-00001. View

10.

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

11.

Yamamoto O, Doi Y, Hamada T, Hisaoka M, Sasaguri Y . An immunohistochemical and ultrastructural study of syringocystadenoma papilliferum. Br J Dermatol. 2002; 147(5):936-45. DOI: 10.1046/j.1365-2133.2002.05027.x. View

12.

Wan P, Garnett M, Roe S, Lee S, Niculescu-Duvaz D, Good V . Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004; 116(6):855-67. DOI: 10.1016/s0092-8674(04)00215-6. View

13.

Mammino J, Vidmar D . Syringocystadenoma papilliferum. Int J Dermatol. 1991; 30(11):763-6. DOI: 10.1111/j.1365-4362.1991.tb04780.x. View

14.

Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A . Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet. 2006; 38(3):294-6. DOI: 10.1038/ng1749. View

15.

Chen X, Mitsutake N, LaPerle K, Akeno N, Zanzonico P, Longo V . Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci U S A. 2009; 106(19):7979-84. PMC: 2674938. DOI: 10.1073/pnas.0900343106. View

16.

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

17.

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N . The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25(16):2078-9. PMC: 2723002. DOI: 10.1093/bioinformatics/btp352. View

18.

Dhomen N, da Rocha Dias S, Hayward R, Ogilvie L, Hedley D, Delmas V . Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethality. Pigment Cell Melanoma Res. 2009; 23(1):112-20. DOI: 10.1111/j.1755-148X.2009.00662.x. View

19.

Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim P, Cho H . Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010; 467(7315):596-9. PMC: 2948082. DOI: 10.1038/nature09454. View